Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shaline Rao

Advanced Heart Failure and Transplant Cardiology Washington, DC Medical Doctor

NPI 1174724827 CMS profile 280254

425 Massachusetts Ave Nw, Washington, DC 20001

Open in the dashboard

General payments

$120,004

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$74,292 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Shaline Rao of Washington, DC is reported in the CMS Open Payments database as having received $120,004 across 227 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $74,292 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,463 32
2024 General $22,712 32
2023 General $26,371 36
2022 General $25,763 57
2021 General $14,629 31
2020 General $7,850 11
2019 General $1,216 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shaline Rao
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Shaline Rao were reported at $21,463. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Shaline Rao Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $1,216 $863 $224–$4,562 $163
2020 $7,850 $452 $122–$3,992 $114
2021 $14,629 $550 $159–$3,571 $132
2022 $25,763 $729 $221–$4,357 $149
2023 $26,371 $1,002 $309–$5,827 $160
2024 $22,712 $931 $273–$5,204 $164
2025 $21,463 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $72,911 85 payments
  2. Alnylam Pharmaceuticals Inc. $16,794 27 payments
  3. Novo Nordisk Inc $6,239 3 payments
  4. Pharmacosmos Therapeutics Inc. $3,785 4 payments
  5. Eli Lilly and Company $3,520 1 payment
  6. Lilly USA, LLC $3,300 5 payments
  7. C. R. Bard, Inc. & Subsidiaries $2,972 1 payment
  8. Abbott Laboratories $2,518 16 payments
  9. Akcea Therapeutics, Inc. $2,292 2 payments
  10. Medtronic, Inc. $1,509 3 payments
  11. Other $4,164 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,838 62 payments
  2. Consulting Fee $24,551 18 payments
  3. Food and Beverage $5,880 129 payments
  4. Travel and Lodging $4,119 15 payments
  5. Honoraria $3,600 1 payment
  6. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $15,896 25 payments
  2. AMVUTTRA $15,117 17 payments
  3. Monoferric $3,785 4 payments
  4. JARDIANCE Diabetes $3,300 5 payments
  5. CARDIOMEMS $1,247 4 payments
  6. JARDIANCE Diabetes $880 1 payment
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $682 6 payments
  8. VYNDAMAX $520 2 payments
  9. VYNDAQEL $234 11 payments
  10. ENTRESTO $225 15 payments
  11. Other $2,012 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

274

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$109,035

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

34.3%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 74 $76,495
Eliquis Apixaban Brand 20 $30,277
Metoprolol Succinate Generic 56 $981
Torsemide Generic 20 $431
Atorvastatin Calcium Generic 34 $304
Furosemide Generic 27 $158
Spironolactone Generic 15 $149
Rosuvastatin Calcium Generic 11 $138
Carvedilol Generic 17 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$51,892

Medicare's payments for the services billed

Medicare patients

164

Average age 74

Services billed

607

60 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 68%
Atrial fibrillation 62%
Chronic kidney disease 60%
Arthritis 59%
Diabetes 46%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $880
  • Lilly USA, LLC $440
$1,320 — —
VYNDAMAX
  • PFIZER INC. $520
$520 — —
Repatha
  • Amgen Inc. $22
$22 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $19
$19 — —
RYBELSUS
  • Novo Nordisk Inc $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record